The expansion of Medicare coverage for Oncocyte's VitaGraft™ Kidney assay is a significant development, as it allows for broader use and reimbursement. This could lead to increased adoption and sales, positively impacting Oncocyte's financial performance. The assay's ability to reduce time to rejection diagnosis in kidney transplant patients is a critical advantage, aligning with the growing importance of early detection in transplant rejection.